Syndax Pharmaceuticals(SNDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SNDX Syndax Pharmaceuticals

Post-Mkt 10-14 17:40:56 EDT

13.53

-0.42

-3.01%

盘后13.60

+0.07+0.52%

17:33 EDT

High14.01	Low13.39	Vol3.04M
Open13.92	D1 Closing13.95	Amplitude4.41%
Mkt Cap1.21B	Tradable Cap1.09B	Total Shares89.30M
T/O41.56M	T/O Rate3.79%	Tradable Shares80.30M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SNDX","market":"US","secType":"STK","nameCN":"Syndax Pharmaceuticals","latestPrice":13.53,"timestamp":1792008000000,"preClose":13.95,"halted":0,"volume":3039862,"hourTrading":{"tag":"盘后","latestPrice":13.6,"preClose":13.53,"latestTime":"17:33 EDT","volume":51312,"amount":693660.297072,"timestamp":1792013593738,"change":0.07,"changeRate":0.005174,"amplitude":0.016268},"delay":0,"changeRate":-0.030107526881720425,"floatShares":80295000,"shares":89297086,"eps":-2.51,"marketStatus":"Post-Mkt","change":-0.42,"latestTime":"10-14 17:40:56 EDT","open":13.92,"high":14.005,"low":13.39,"amount":41560734.87573,"amplitude":0.044086,"askPrice":13.6,"askSize":242,"bidPrice":13.2,"bidSize":3,"shortable":0,"etf":0,"ttmEps":-2.51,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1792022400000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1456981200000,"exchange":"NASDAQ","adjPreClose":13.95,"preHourTrading":{"tag":"盘前","latestPrice":13.75,"preClose":13.95,"latestTime":"09:26 EDT","volume":3188,"amount":44174.381728,"timestamp":1791984368994,"change":-0.2,"changeRate":-0.014337,"amplitude":0.048746},"postHourTrading":{"tag":"盘后","latestPrice":13.6,"preClose":13.53,"latestTime":"17:33 EDT","volume":51312,"amount":693660.297072,"timestamp":1792013593738,"change":0.07,"changeRate":0.005174,"amplitude":0.016268},"volumeRatio":1.083267,"impliedVol":0.8006,"impliedVolPercentile":0.8287},"requestUrl":"/m/hq/s/SNDX","defaultTab":"news","newsList":[{"id":"1100541578","title":"Syndax Drops 17% After Its IPF Growth Bet Fails","url":"https://stock-news.laohu8.com/highlight/detail?id=1100541578","media":"Bellwether Stocks Movement","labels":["videos"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100541578?lang=en_us&edition=fundamental","pubTime":"2026-10-14 18:32","pubTimestamp":1791973963,"startTime":"0","endTime":"0","summary":"","market":"us","thumbnail":"https://news-video-sg.skytigris.cn/videos/covers/3630.webp","type":0,"news_type":0,"thumbnails":["https://news-video-sg.skytigris.cn/videos/covers/3630.webp"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"Syndax Drops 17% After Its IPF Growth Bet Fails","news_tag":"videos","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SSNLF","WDC","SNDU","MUG","09347","MULL","WDCX","WDCC","STX","SNDX","SNDK","STXX","SNDG","SNDQ","MU","STXU","MUD","07747","SNXX","MUZ","SNDC","MIC","07709","SMSD.UK","STXL","MUYY","MUU"],"isVideo":true,"video":{"duration":194,"video_url":"https://news-video-sg.skytigris.cn/videos/remotion/3630/render_3630_1791973389223.mp4","video_thumbnail":"https://news-video-sg.skytigris.cn/videos/covers/3630.webp","audio_url":"https://news-video-sg.skytigris.cn/videos/remotion/3630/tts/voiceover_3fd661b461aa78c3.mp3","isAI":true},"gpt_icon":0},{"id":"2675369038","title":"Top Midday Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2675369038","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675369038?lang=en_us&edition=fundamental","pubTime":"2026-10-14 02:01","pubTimestamp":1791914489,"startTime":"0","endTime":"0","summary":"UBS downgraded Acadia Pharmaceuticals'  shares one notch to neutral and set a $23 price target.Acadia shares fell 4.7% amid intraday trading volume of over 903,000, versus a daily average of about 1.8 million.Applied Materials  said Monday it opened its new $5 billion semiconductor research and development center at its Sunnyvale, California, campus to accelerate the development and commercialization of chipmaking technologies for AI.The company expects revenue to double over the next few years without a proportional increase in its workforce as it expands its use of artificial intelligence, Bloomberg reported Monday.Shares slumped 8%, with intraday trading volume climbing to over 6.2 million, versus a daily average of about 6.8 million.Syndax Pharmaceuticals  said Monday its phase 2 trial of axatilimab in idiopathic pulmonary fibrosis failed to meet its primary endpoint of annualized forced vital capacity decline, and the company does not plan further development for the indication.Sh","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1674673428.USD","APMI","LU2089985449.USD","LU1267930813.SGD","LU1153585028.USD","LU1815336760.USD","LU0738911758.USD","LU1974910355.USD","RDVY","LU1868837136.USD","LU0889565833.HKD","EPAI","AMA","LU1868836591.USD","AMAT","LU2106854487.HKD","SOXQ","TDV","XNTK","LU0158827781.USD","LU0097036916.USD","LU2023250843.SGD","LU2931357623.SGD","LU2065171402.SGD","AMAU","LU0127658192.USD","TINY","SG9999002232.USD","LU0354030438.USD","SHOC","SNDX","LU1721428933.USD","LU2543165471.USD","QQQG","LU1046421795.USD","WUGI","LU0061474960.USD","RDVI","IE00BQXX3C00.GBP","LU2065170008.USD","SMH","LU0661504455.SGD","LU0276348264.USD","PSI","BK4518","BK4139","ACAD","BK4147","LU0096364046.USD","CHPS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675936329","title":"Syndax Pharmaceuticals Stock Plunges. a Failed Trial Deals Blow to Growth Plans.","url":"https://stock-news.laohu8.com/highlight/detail?id=2675936329","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675936329?lang=en_us&edition=fundamental","pubTime":"2026-10-13 23:24","pubTimestamp":1791905040,"startTime":"0","endTime":"0","summary":"Syndax Pharmaceuticals stock plunged on Tuesday after the drugmaker reported disappointing trial results for a lung disease treatment, dealing a setback to its efforts to expand the market for one of ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0237698245.USD","SNDX","LU1868836914.USD","LU0432979614.USD","LU0306806265.USD","LU0456855351.SGD","LU1571399168.USD","LU1983299246.USD","LU0114720955.EUR","LU1261432733.SGD","LU0868494617.USD","LU1074936037.SGD","IHE","LU2125154778.USD","LU2242652126.USD","LU0225284248.USD","LU2596442595.SGD","SNY","LU1868837136.USD","IE00BJT1NW94.SGD","LU1670710588.SGD","LU2360032135.SGD","AVLN","BK4588","LU0321505439.SGD","IE00BFXG1179.USD","LU1585245621.USD","IE00BJJMRZ35.SGD","LU1868836591.USD","LU2125154935.USD","LU2242646821.SGD","BK4581","FTXH","LU1236620750.USD","LU1291159041.SGD","BMY","BK4559","LU0267386448.USD","LU1430594728.SGD","LU1718418525.SGD","LU1989771016.USD","LU1323610961.USD","LU1670710661.SGD","LU0321505868.SGD","LU1868836757.USD","LU1670711123.USD","IE00BSNM7G36.USD","BK4534","LU0061475181.USD","LU0096364046.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675363988","title":"Syndax Pharmaceuticals Selloff After IPF Trial Failure Appears 'Overdone,' BofA Securities Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2675363988","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675363988?lang=en_us&edition=fundamental","pubTime":"2026-10-13 23:12","pubTimestamp":1791904328,"startTime":"0","endTime":"0","summary":"Syndax Pharmaceuticals  selloff after the company ended development of axatilimab in idiopathic pulmonary fibrosis appears \"overdone\" because the program carried \"little in valuation,\" while the company's Revuforj opportunity remains intact, BofA Securities said in a note Tuesday.Shares are trading down about 18% after the company said a phase 2 trial of axatilimab in IPF failed to meet its primary endpoint of annualized forced vital capacity decline.The investment firm said the IPF trial had taken on an \"outsized role\" in the narrative as a diversification catalyst, but its high-risk profile meant it was largely excluded from the Wall Street models.The main debate still centers on acute myeloid leukemia opportunities, with Revuforj's ability to capture share across relapsed or refractory, post-transplant and first-line settings, according to the note.BofA Securities maintained a buy rating on Syndax Pharmaceuticals, while lowering its price target to $23 from $26.Price: 13.56, Change:","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","SNDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675368788","title":"Syndax Pharmaceuticals Down over 17%, on Pace for Largest Percent Decrease Since May 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2675368788","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675368788?lang=en_us&edition=fundamental","pubTime":"2026-10-13 22:49","pubTimestamp":1791902940,"startTime":"0","endTime":"0","summary":"Syndax Pharmaceuticals Inc.  is currently at $13.61, down $2.94 or 17.76%--Would be lowest close since Oct. 30, 2025, when it closed at $13.39--On pace for largest percent decrease since May 6, 2025, when it fell 21.59%--Currently down five of the past six days--Currently down two consecutive days; down 19.89% over this period--Worst two day stretch since the two days ending May 7, 2025, when it fell 26.38%--Down 27.6% month-to-date--Down 35.21% year-to-date; on pace for worst year since 2024, when it fell 38.82%--Down 53.03% from its all-time closing high of $28.98 on Feb. 1, 2023--Down 11.09% from 52 weeks ago , when it closed at $15.31--Down 45.88% from its 52-week closing high of $25.15 on April 2, 2026--Up 3.83% from its 52-week closing low of $13.11 on Oct. 27, 2025--Traded as low as $13.49; lowest intraday level since Nov. 4, 2025, when it hit $13.15--Down 18.49% at today's intraday low; largest intraday percent decrease since May 6, 2025, when it fell as much as 22.66%All data ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SNDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675357525","title":"Syndax valuation unchanged after trial miss, says H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2675357525","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675357525?lang=en_us&edition=fundamental","pubTime":"2026-10-13 21:20","pubTimestamp":1791897630,"startTime":"0","endTime":"0","summary":"H.C. Wainwright reiterates a Buy rating on Syndax (SNDX) with a $38 price target after the Phase 2 study of axatilimab in idiopathic pulmonary fibr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/syndax-valuation-unchanged-after-trial-miss-says-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/syndax-valuation-unchanged-after-trial-miss-says-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TACU","BK4139","CDIG","SNDX","TSPA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675575263","title":"Syndax selloff brings attractive entry point, says Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2675575263","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675575263?lang=en_us&edition=fundamental","pubTime":"2026-10-13 21:15","pubTimestamp":1791897318,"startTime":"0","endTime":"0","summary":"Citi views the selloff in Syndax (SNDX) shares after the Phase 2 study of axatilimab in idiopathic pulmonary fibrosis missed its primary endpoint a...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/syndax-selloff-brings-attractive-entry-point-says-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/syndax-selloff-brings-attractive-entry-point-says-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SNDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675351496","title":"BofA Securities Adjusts Syndax Pharmaceuticals PT to $23 From $26, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2675351496","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675351496?lang=en_us&edition=fundamental","pubTime":"2026-10-13 20:09","pubTimestamp":1791893343,"startTime":"0","endTime":"0","summary":"Syndax Pharmaceuticals Inc (SNDX) has an average rating of buy and mean price target of $37.55, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research fro","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SNDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675356378","title":"Syndax Pharmaceuticals Price Target Maintained with a $38.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2675356378","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675356378?lang=en_us&edition=fundamental","pubTime":"2026-10-13 19:09","pubTimestamp":1791889740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SNDX/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675635338","title":"Syndax price target lowered to $23 from $26 at BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2675635338","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675635338?lang=en_us&edition=fundamental","pubTime":"2026-10-13 18:20","pubTimestamp":1791886823,"startTime":"0","endTime":"0","summary":"BofA analyst Jason Zemansky lowered the firm’s price target on Syndax (SNDX) to $23 from $26 and keeps a Buy rating on the shares after the company...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/syndax-price-target-lowered-to-23-from-26-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/syndax-price-target-lowered-to-23-from-26-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SNDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675383133","title":"Stocks to Watch: Syndax Pharmaceuticals, FormFactor, Navitas Semiconductor","url":"https://stock-news.laohu8.com/highlight/detail?id=2675383133","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675383133?lang=en_us&edition=fundamental","pubTime":"2026-10-13 06:55","pubTimestamp":1791845700,"startTime":"0","endTime":"0","summary":"Syndax Pharmaceuticals said a drug to treat idiopathic pulmonary fibrosis missed its primary endpoint in a Phase 2 trial. Shares plunged 19% to $13.34 in after-hours trading on Monday.Teradyne agreed to invest $300 million in FormFactor as part of a partnership to work on improving semiconductor testing. FormFactor shares gained 3.6% to $134.90.Navitas Semiconductor released its latest power-delivery board designed for Nvidia infrastructure. The stock was up 4% at $10.39.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FORM","BK4139","LU1815336760.USD","IE00BN0W2V16.EUR","NVTC","IE00B7SZL793.SGD","PSCT","LU1861558580.USD","IE00B66KJ199.SGD","EPAI","LU0444971666.USD","IE00BMPRXQ63.HKD","TER","IE00BMPRXN33.USD","IE00BN0W2W23.USD","IE00BMPRXR70.SGD","BK4585","TERC","SNDX","BK4548","IE0031619046.USD","LU1642822529.SGD","LU1861559042.SGD","NVTX","BK4147","LU0957808578.USD","IE00BN0W2T93.GBP","TERG","IE00B19Z4B17.USD","LU1878469433.USD","BK4588","IE00B19Z6F94.USD","NVTS","BK4602","BK4141","BK4543","FOMG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675800965","title":"Syndax Says Mid-Stage Trial of Lung Disease Treatment Fails Main Goal, Ends Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2675800965","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675800965?lang=en_us&edition=fundamental","pubTime":"2026-10-13 04:38","pubTimestamp":1791837528,"startTime":"0","endTime":"0","summary":"Syndax says mid-stage trial of lung disease treatment fails main goal, ends developmentOct 12 (Reuters)-Syndax PharmaceuticalsSNDX.Osaid on Monday it will stop developing a treatment for idiopathic pu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261012:nL4N45Y199:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INCY","BK4532","IDNA","BK4139","BK4588","SNDX","BK4585","BK4550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675809800","title":"Syndax says Phase 2 idiopathic pulmonary fibrosis study misses endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2675809800","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675809800?lang=en_us&edition=fundamental","pubTime":"2026-10-13 04:10","pubTimestamp":1791835857,"startTime":"0","endTime":"0","summary":"Syndax (SNDX) Pharmaceuticals announced that the MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis did not meet its primary endp...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/syndax-says-phase-2-idiopathic-pulmonary-fibrosis-study-misses-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/syndax-says-phase-2-idiopathic-pulmonary-fibrosis-study-misses-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL","BBC","SNDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675360800","title":"Syndax to end development of axatilimab in idiopathic pulmonary fibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2675360800","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675360800?lang=en_us&edition=fundamental","pubTime":"2026-10-13 04:05","pubTimestamp":1791835521,"startTime":"0","endTime":"0","summary":"16:03 EDT Syndax (SNDX) to end development of axatilimab in idiopathic pulmonary fibrosis Published first on TheFly – the ultimate source for real-...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/syndax-to-end-development-of-axatilimab-in-idiopathic-pulmonary-fibrosis-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/syndax-to-end-development-of-axatilimab-in-idiopathic-pulmonary-fibrosis-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SNDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675800877","title":"Syndax sinks 15% to $14 after idiopathic pulmonary fibrosis miss","url":"https://stock-news.laohu8.com/highlight/detail?id=2675800877","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675800877?lang=en_us&edition=fundamental","pubTime":"2026-10-13 04:05","pubTimestamp":1791835516,"startTime":"0","endTime":"0","summary":"16:03 EDT Syndax (SNDX) sinks 15% to $14 after idiopathic pulmonary fibrosis miss Published first on TheFly – the ultimate source for real-time, ma...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/syndax-sinks-15-to-14-after-idiopathic-pulmonary-fibrosis-miss-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/syndax-sinks-15-to-14-after-idiopathic-pulmonary-fibrosis-miss-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SNDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675807255","title":"Syndax Axatilimab Misses Primary Endpoint in Phase 2 IPF Trial, Drops Further Development in Indication","url":"https://stock-news.laohu8.com/highlight/detail?id=2675807255","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675807255?lang=en_us&edition=fundamental","pubTime":"2026-10-13 04:01","pubTimestamp":1791835283,"startTime":"0","endTime":"0","summary":"Syndax axatilimab misses primary endpoint in Phase 2 IPF trial, drops further development in indicationSyndax reported topline results from its MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmon","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261012:nNDLb5qrsJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00BQXX3D17.EUR","LU2210149790.SGD","IE00B64PRP62.GBP","SG9999014005.SGD","SG9999014039.USD","SNDX","IE00BKPKM429.USD","BK4112","IE00BN0W2V16.EUR","LU0314104364.USD","LU2095319765.USD","BK4585","SG9999014013.SGD","IE00BN0W2W23.USD","IE00BQXX3C00.GBP","NDAQ","SG9999014021.USD","BCDF","IE00BQXX3F31.USD","IE00BN0W2T93.GBP","LU2210150020.SGD","BK4588","IE00B3QW5Z07.USD","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675807284","title":"Syndax Announces Topline Results from Maxpire Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2675807284","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675807284?lang=en_us&edition=fundamental","pubTime":"2026-10-13 04:01","pubTimestamp":1791835260,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261012:nTUA2JH2NV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SNDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675807236","title":"Syndax Pharmaceuticals - Axatilimab Continues in Multiple Cgvhd Trials with Results Expected Later This Year and Early 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2675807236","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675807236?lang=en_us&edition=fundamental","pubTime":"2026-10-13 04:01","pubTimestamp":1791835260,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261012:nTUA2JH2NV:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SNDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675807235","title":"Syndax Pharmaceuticals - Maxpire Phase 2 Trial of Axatilimab in Ipf Does not Meet Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2675807235","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675807235?lang=en_us&edition=fundamental","pubTime":"2026-10-13 04:01","pubTimestamp":1791835260,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261012:nTUA2JH2NV:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SNDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675380723","title":"Syndax Pharmaceuticals - Will not Pursue Further Development of Axatilimab in Ipf","url":"https://stock-news.laohu8.com/highlight/detail?id=2675380723","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675380723?lang=en_us&edition=fundamental","pubTime":"2026-10-13 04:01","pubTimestamp":1791835260,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261012:nTUA2JH2NV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SNDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.syndax.com","stockEarnings":[{"period":"1week","weight":-0.1969},{"period":"1month","weight":-0.2327},{"period":"3month","weight":-0.4069},{"period":"6month","weight":-0.4141},{"period":"1year","weight":-0.0822},{"period":"ytd","weight":-0.336}],"compareEarnings":[{"period":"1week","weight":-0.0014},{"period":"1month","weight":0.018},{"period":"3month","weight":0.0307},{"period":"6month","weight":0.1088},{"period":"1year","weight":0.1734},{"period":"ytd","weight":0.1409}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.039298},{"month":2,"riseRate":0.7,"avgChangeRate":0.080379},{"month":3,"riseRate":0.6,"avgChangeRate":0.053723},{"month":4,"riseRate":0.363636,"avgChangeRate":0.005788},{"month":5,"riseRate":0.363636,"avgChangeRate":-0.025528},{"month":6,"riseRate":0.545455,"avgChangeRate":0.007318},{"month":7,"riseRate":0.545455,"avgChangeRate":0.003097},{"month":8,"riseRate":0.636364,"avgChangeRate":0.097617},{"month":9,"riseRate":0.454545,"avgChangeRate":-0.030865},{"month":10,"riseRate":0.181818,"avgChangeRate":-0.094162},{"month":11,"riseRate":0.6,"avgChangeRate":0.04592},{"month":12,"riseRate":0.5,"avgChangeRate":0.035938}],"exchange":"NASDAQ","name":"Syndax Pharmaceuticals","nameEN":"Syndax Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Syndax Pharmaceuticals(SNDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Syndax Pharmaceuticals(SNDX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Syndax Pharmaceuticals,SNDX,Syndax Pharmaceuticals股票,Syndax Pharmaceuticals股票老虎,Syndax Pharmaceuticals股票老虎国际,Syndax Pharmaceuticals行情,Syndax Pharmaceuticals股票行情,Syndax Pharmaceuticals股价,Syndax Pharmaceuticals股市,Syndax Pharmaceuticals股票价格,Syndax Pharmaceuticals股票交易,Syndax Pharmaceuticals股票购买,Syndax Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Syndax Pharmaceuticals(SNDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Syndax Pharmaceuticals(SNDX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}